We are thrilled to announce that 7 Hills was awarded $4.7MM by the Cancer Prevention and Research Institute of Texas to advance our new approach to safely augmenting cell/gene therapies into the clinic with 7HP935! We are at American Society of Clinical Oncology (ASCO) today and tomorrow, so be sure to find our CEO Upendra Marathi and say hi! #asco2024 #asco24
7 Hills Pharma
Biotechnology Research
Houston, Texas 746 followers
First-in-concept platform of oral drugs to overcome immunotherapy resistance
Über uns
7 Hills Pharma is a clinical-stage pharmaceutical company developing first-in-concept, oral immune stimulants to augment a broad range of immunotherapies for the treatment of drug-resistant solid tumors and prevention of infectious diseases. Our compounds are selective, allosteric, systemic activators of the integrins LFA-1 and VLA-4 that have been shown in preclinical models to augment the effectiveness of prophylactic vaccines for influenza, COVID-19, Tuberculosis, and Chagas disease, as well as checkpoint inhibitors for solid tumors. Our lead molecule, 7HP349, has completed a Phase I first-in-human clinical trial, demonstrating oral bioavailability and an exceptional safety profile at exposures well exceeding therapeutic levels.
- Website
-
http://www.7hillspharma.com
External link for 7 Hills Pharma
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 2-10 Mitarbeiter
- Hauptsitz
- Houston, Texas
- Typ
- In Privatbesitz
Standorte
-
Primäre
Wegbeschreibung erhalten
2450 Holcombe Blvd
Houston, Texas 77021, US